AZN: TEZSPIRE Reduces Nasal Polyp Severity And Surgery Need In CRSwNP Patients In Phase III Trial

(RTTNews) - The Phase III WAYPOINT trial results revealed that AstraZeneca (AZN.L, AZN) and Amgen's (AMGN) TEZSPIRE (tezepelumab-ekko) significantly decreased nasal polyp severity, reduced the necessity for subsequent surgeries, and minimized systemic corticosteroid use in patien https://www.nasdaq.com/articles/azn-tezspire-reduces-nasal-polyp-severity-and-surgery-need-crswnp-patients-phase-iii-trial